Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms... Show more
a holding company
Industry MedicalSpecialties
A.I.dvisor indicates that over the last year, MEDP has been loosely correlated with TMO. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if MEDP jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To MEDP | 1D Price Change % | ||
|---|---|---|---|---|
| MEDP | 100% | +0.23% | ||
| TMO - MEDP | 61% Loosely correlated | +0.35% | ||
| CRL - MEDP | 57% Loosely correlated | +1.17% | ||
| A - MEDP | 44% Loosely correlated | +0.66% | ||
| RVTY - MEDP | 44% Loosely correlated | +1.66% | ||
| BRKR - MEDP | 43% Loosely correlated | +2.10% | ||
More | ||||
MEDP's Aroon Indicator triggered a bullish signal on September 01, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 260 similar instances where the Aroon Indicator showed a similar pattern. In 217 of the 260 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +1.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in 238 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
MEDP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MEDP as a result. In 54 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 55%.
The Moving Average Convergence Divergence Histogram (MACD) for MEDP turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 32 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
MEDP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 24 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (39.683) is normal, around the industry mean (72.578). P/E Ratio (36.187) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (2.929) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.